Novel immune therapies in MDS and challenges in this space
Myelodysplastic syndromes (MDS) represent a group of heterogeneous diseases which remain a challenge to treat, and several novel therapies are being explored for the treatment of patients, especially those with relapsed/refractory (R/R) or high-risk disease. Immune therapies including CAR-T therapy…
The importance of CD47 in MDS and other targets of interest
CD47 is a cell surface protein which is overexpressed in several cancer cells and appears to play an important role in a variety of hematological malignancies, including acute myeloid leukemia (AML), lymphoma, and myelodysplastic syndromes (MDS). Currently, several anti-CD47 agents are under invest…
Highlights in MDS at ASH 2022: Treating lower-risk & higher-risk disease, trial updates, & more
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.
In this podcast, David Sallman, MD, Moffitt Can…
iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (AL…
The role of the innate immune system in MDS
Myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases which remain a challenge to treat, and immune dysregulation has been found to play a key role in the pathogenesis of MDS. There is a growing interest, by researchers, as well as clinicians, to better understand the role of …
The need for more effective first-line therapies in MDS
The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early diagnosis and intervention are important factors in MDS. Several experts agree that there is a need to develop more effective first-line therapies, and numerous cli…
Immune dysregulation and targeting in MDS
Myelodysplastic syndromes (MDS) are a type of rare and heterogeneous hematological malignancy, and immune dysregulation plays a major role in the development of this disease and progression to acute myeloid leukemia (AML). Several novel targets are being explored in this field with the aim of incre…
ASH 2021: what did ASH 2021 mean for MDS?
With high rates of relapse in patients with myelodysplastic syndromes (MDS), there is a great unmet need for novel treatments that are effective and tolerable, despite the heterogeneous nature of MDS. A recent shift in personalized medicine has resulted in a number of clinical trials investigating …
Driving Progress in AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL
Recorded on April 9, 2026
David Sallman, MD
Associate Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL
In this exciting episode, Dr. David Sallman from Moffitt Cancer Center takes a deep d…
S1 Ep234: What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
At the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, CancerNetwork® sat down with a variety of experts to discuss the latest data and emerging trends surrounding the management of different hematologic malignancies. Speakers and presentations covered everything from second primary m…
PODKAST SØGEMOTOR
Du kan bruke vår nettsted til å søke etter3,830,122podkaster og196,585,597episoder etter personer, steder eller emner.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
REDIG
Takk fordi du hjelper med å holde podkast-databasen oppdatert.
